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background: Human embryo implantation is regulated by estradiol (E2), progesterone and locally produced mediators including
interleukin-1b (IL-1b). Interactions between the estrogen receptor (ER) and NF kappa B (NFkB) signalling pathways have been reported
in other systems but have not been detailed in human endometrium.
methods and results: Real-time PCR showed that mRNA for the p65 and p105 NFkB subunits is maximally expressed in endo-
metrium from the putative implantation window. Both subunits are localized in the endometrial epithelium throughout the menstrual cycle.
Reporter assays for estrogen response element (ERE) activity were used to examine functional interactions between ER and NFkB in telo-
merase immortalized endometrial epithelial cells (TERT-EEC). E2 and IL-1b treatment of TERT-EECs enhances ERE activity by a NFkB and ER
dependent mechanism; this effect could be mediated by ERa or ERb. E2 and IL-1b also positively interact to increase endogenous gene
expression of prostaglandin E synthase and c-myc. This is a gene-dependent action as there is no additive effect on cyclin D1 or progesterone
receptor expression.
conclusion: In summary, we have established that NFkB signalling proteins are expressed in normal endometrium and report that IL-
1b can enhance the actions of E2 in a cell line derived from healthy endometrium. This mechanism may allow IL-1b, possibly from the devel-
oping embryo, to modulate the function of the endometrial epithelium to promote successful implantation, for example by regulating pros-
taglandin production. Aberrations in the interaction between the ER and NFkB signalling pathways may have a negative impact on
implantation contributing to pathologies such as early pregnancy loss and infertility.
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Introduction
The human endometrium is a dynamic tissue that undergoes cycles of
proliferation, differentiation, breakdown and repair (Jabbour et al.,
2006; van Mourik et al., 2009). The development of the endometrium
in preparation for implantation of the fertilized conceptus is under the
control of the sex steroid hormones, estradiol and progesterone.
Implantation occurs during the mid-late secretory phase of the men-
strual cycle (the ‘implantation window’) and is characterized as an
inﬂammatory event associated with increased expression of inﬂamma-
tory mediators and immune cell inﬁltration (van Mourik et al., 2009).
The actions of estrogens on the endometrium are mediated by
estrogen receptors (ER)a and ERb both of which are expressed in epi-
thelial and stromal cells (Critchley et al., 2001, 2002; Critchley and
Saunders 2009). Immunoexpression of ERa varies during the normal
cycle with intense staining in epithelial and stromal cells during the pro-
liferative phase but a marked reduction in the functional layer during
the late secretory phase (Lessey et al., 1988; Critchley et al., 2001).
In contrast, ERb alone is expressed in both endothelial and uterine
natural killer cells (Henderson et al., 2003) and appears similar in epi-
thelial and stromal cells during both the proliferative and secretory
phases (Critchley et al., 2002). As a result ERb appears to be the
& The Author 2009. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Human Reproduction, Vol.25, No.2 pp. 510–518, 2010
Advanced Access publication on December 2, 2009 doi:10.1093/humrep/dep421predominant isoform in both the glandular (Critchley et al., 2002) and
surface (Bombail et al., 2008) epithelium during the implantation
window.
Inﬂammatory events including immune cell inﬁltration can be
mediated via activation of NF kappa B (NFkB)-dependent gene tran-
scription. NFkB is a dimeric transcription factor consisting of homo- or
hetero-dimeric complexes of the Rel family of proteins; in the inactive
state the complex is sequestered in the cytoplasm by a family of
endogenous inhibitors, called IkBs. Previous studies have reported
that expression of the NFkB subunits, p65 (Rel A) and p50, are
increased during the mid secretory phase (Laird et al., 2000; Page
et al., 2002) although expression of IkBa is reported to fall at this
time (Page et al., 2002). These semi-quantitative immunohistochemical
studies would be consistent with a role for NFkB activation during the
implantation window. However, this has not been conﬁrmed using
quantitative analysis.
Estrogens are well documented as having anti-inﬂammatory effects
whereas activated NFkB initiates and maintains cellular inﬂammatory
responses (Biswas et al., 2005; Harnish, 2006). Evidence for the anti-
inﬂammatory effects of estrogens was highlighted by the observation
that pregnancy reduces the symptoms of rheumatoid arthritis, multiple
sclerosis and inﬂammatory bowel disease (Harnish, 2006). One mech-
anism by which estrogens can modulate inﬂammatory events has been
described in articles documenting that reciprocal inhibitory cross-talk
exists between NFkB and ER both in vitro (Harnish et al., 2000;
Feldman et al., 2007; Quaedackers et al., 2007) and in vivo (Evans
et al., 2001). For example, direct interactions between ERa and p65
(Quaedackers et al., 2007), as well as cofactor involvement and modu-
lation of IkBa expression by E2 (Nakshatri et al., 1997; Sun et al.,
1998) have been reported. However, more recent studies have also
reported that a positive interaction between NFkB and ER signalling
can occur. For example, Adamson et al. (2008) found that treatment
with E2 plus TNFa had a synergistic effect on estrogen response
element (ERE)-dependent activation of the human prolactin gene in
GH3 pituitary cells. Similarly, proinﬂammatory cytokines (TNFa,
IL-1b or IL-6) and E2 also act synergistically to up-regulate expression
of prostaglandin E synthase (PGES) mRNA levels in MCF7 breast
cancer cells (Frasor et al., 2008). As inﬂammation and steroid
hormone action both play critical roles in endometrial function, we
aimed to investigate whether cross-talk between NFkB and ER signal-
ling occurs in endometrial epithelial cells and whether this is inhibitory
or stimulatory in nature.
Materials and Methods
Patients and tissue collection
Endometrial samples (n ¼ 24) was collected from women undergoing pro-
cedures for benign gynaecological conditions. All women had regular men-
strual cycles and had not undergone hormonal treatment in the 3 months
preceding biopsy. Histological dating of the samples was performed
according to the criteria of Noyes (1950). Serum samples collected at
the time of endometrial biopsy were used for determination of circulating
estradiol and progesterone concentrations by radioimmunoassay (Table I).
These circulating steroid hormone levels were consistent with the histo-
logical assessment that was undertaken by an expert histologist. Tissues
were either ﬁxed in 4% neutral buffered formalin overnight at 48C and
embedded in parafﬁn wax according to standard procedures or placed
in RNA Later (Ambion/Applied Biosystems, Warrington, UK) for sub-
sequent RNA extraction. Written informed consent was obtained from
all patients and ethical approval was granted by the Lothian research
ethics committee.
Cell culture
Telomerase immortalized endometrial epithelial cells (TERT-EEC) were
originally derived from normal endometrium obtained during the prolifera-
tive phase. These cells express ERa,E R b and PR mRNA and protein
(Hombach-Klonisch et al., 2005; Collins, unpublished). Cells were
seeded in 24 well culture plates (Corning-Costar) at a density of 1  
10
5/well in Hams F-10 medium supplemented with 10% charcoal stripped
fetal calf serum (Sigma, Dorset, UK), insulin–transferrin–selenium (ITS,
1 ; Lonza, Slough, UK), penicillin/streptomycin and gentamycin (Sigma).
Ishikawa cells (ECACC, Salisbury, UK) were originally derived from the
endometrial adenocarcinoma from a 39-year-old woman (Nishida et al.,
1985). In our hands, this line of Ishikawa cells expresses ERa,E R b and
PR; cells were seeded in 24 well culture plates at a density of 1   10
5/
well in DMEM medium supplemented with 10% charcoal stripped fetal
calf serum, L-glutamine, penicillin/streptomycin and non-essential amino
acids (1%).
Luciferase reporter assays
An adenoviral vector containing a 3xERE-tk-luciferase reporter gene was
prepared by subcloning a piece of DNA containing the ERE promoter
and luciferase sequences from a plasmid that was a kind gift from Professor
DP McDonnell [(Hall and McDonnell, 1999), Duke University NC, USA]
into the adenoviral genome (pBHGloxDE1,3Cre, Microbix) that was pro-
pagated in Hek293 cells according to standard methods. An adenovirus
containing an NFkB response element linked to a luciferase reporter
gene was obtained from Vector BioLabs (Philadelphia, USA). The
control adenovirus (Ad-d1703) and an adenovirus containing a dominant
negative IkBa mutant (Ad-IkBa) have been described previously (Jobin
et al., 1997; Henriksen et al., 2004). Luciferase was detected using the
Bright-Glo luciferase assay system (Promega, Southampton, UK) as
detailed in the manufacturer’s instructions.
Three separate experimental protocols were used to examine the
effects of E2 and IL-1b on ERE activity in TERT-EEC. In all experiments,
cells were infected with adenovirus containing the ERE-luc expression con-
struct. The total multiplicity of infection (MOI) was 100.
(i) Cells were left untreated or treated with the ER antagonist, ICI
182720 (10
26 M), for 1 h. Thereafter cells were either left untreated
or incubated with vehicle (DMSO), E2 (10
28 M), IL-1b (0.1 ng/ml)
or E2 þ IL-1b for a further 24 h.
(ii) Cells were co-infected with a control adenovirus (Ad-d1703) or an
adenovirus containing a dominant negative IkBa mutant (Ad-IkBa)
at a total MOI of 100. The following day, cells were either left
untreated or treated with vehicle (DMSO), E2 (10
28 M; Sigma),
IL-1b (0.1 ng/ml; Peprotech, London, UK) or E2 þ IL-1b and incu-
bated for a further 24 h.
(iii) Cells were co-infected with a control adenovirus (Ad-d1703) or an
adenovirus containing a dominant negative IkBa mutant (Ad-IkBa)
at a total MOI of 100. Cells were either left untreated or treated
with vehicle (DMSO), IL-1b (0.l ng/ml), the ERa selective agonist,
PPT (4,40,400-(4-propyl-[
1H]-pyrazole-1,3,5-triyl tris-phenol (Kraichely
et al., 2000)) at 10
28 M, the ERb selective agonist, DPN
(2,3-bis(4-hydroxyphenyl)-propionitrile (Meyers et al., 2001)) at
10
27 M, or combinations of these treatments (PPT þ IL-1b or
DPN þ IL-1b) and incubated for 24 h.
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optimal response in the ERE reporter assay in pilot studies. In additional
complementary experiments, Ishikawa cells were infected with ERE and
either Ad-d1703 or Ad-IkBa (total MOI ¼ 50) and treated as in (ii).
The impact of treatments on NFkB signalling was investigated by infect-
ing TERT-EECs with the NFkB-luc reporter at an MOI of 50; cells were
treated with vehicle, E2 (10
28 M), IL-1b (0.1 ng/ml) or E2 þ IL-1b for
24 h. Each experiment was repeated on three separate occasions.
Endogenous gene expression
TERT-EEC were seeded in six well culture plates at a density of 3   10
5/
well in Hams-F10 medium supplemented with 10% charcoal stripped fetal
calf serum, ITS (1 ), penicillin/streptomycin and gentamycin. The follow-
ing day cells were either left untreated or incubated with vehicle (DMSO),
E2 (10
28 M), IL-1b (0.lng/ml) or both factors at the same time for 2, 4
and 8 h. The experiment was repeated three times.
Quantitative RT–PCR
RNA was extracted from cells or endometrial tissues using RNeasy mini
kits (Qiagen,); RNA samples were treated with DNase
I. Complementary DNA was prepared from 400 ng of template RNA in
20 ml reactions containing: RT buffer (1 ), magnesium chloride
(5.5 mM), dNTP mix (2 mM), random hexamers (2.5 mM), RNase inhibi-
tor (0.4 U/ml) and Multiscribe reverse transcriptase (1.25 U/ml; Applied
Biosystems, Cheshire, UK). Each cDNA preparation included two con-
trols: one containing template RNA but no reverse transcriptase (RT nega-
tive) and the other containing reverse transcriptase with water in place of
template RNA (RT H2O).
PCR reaction mixtures contained Taqman Master-mix (1 ; Applied
Biosystems), forward and reverse primers (Eurogentec) and probe (Euro-
gentec/Roche) for the gene of interest and forward and reverse primers
and probe for ribosomal 18s (Applied Biosystems). Expression of the
gene of interest was related to expression of 18S ribosomal RNA and
to an internal control sample using the 2
2DDCt method. Controls included
the RT controls detailed above and a PCR no template control (water in
place of cDNA). PCR reactions were run on an ABI 7900 Sequence
Detection System (Perkin-Elmer Applied Biosystems, USA). Primer and
probe sequences are detailed in Supplementary data, Table SI.
Immunohistochemistry
Immunohistochemical localization of p65, p105/p50 and IkBa was per-
formed on endometrial (n ¼ 17) sections as follows. Antigen retrieval was
carried out using a microwave (15 min in antigen unmasking solution,
Vector, Peterborough, UK); endogenous peroxidase activity was blocked
with 3% hydrogen peroxide (Sigma-Aldrich, Dorset, UK). Additional pre-
treatmentsinvolvedincubationwithsolutionsfromtheavidinbiotinblocking
kit (Vector)andtheDakoCytomationproteinblock(Dako,Ely,UK),10 min
each at room temperature. Sections were incubated overnight at 48C with
eitherrabbit-antip65(1:500;SantaCruz),rabbitanti-p105/50(1:500;NLS,
Santa Cruz) or rabbit anti-IkBa (1:300; E130, Abcam, Cambridge, UK)
diluted in REAL antibody diluent (Dako). For negative controls, the
primary antibody was substituted with antibody diluent alone. Sections
were washed and incubated with a biotinylated goat anti-rabbit secondary
antibody and the avidin biotin peroxidase detection system, both for
30 min at room temperature (Vectastain Elite ABC, Vector). Positive stain-
ingwasdetectedusingdiaminobenzidine(ImmPACTDAB;Vector)andsec-
tions were counterstained with Harris’ haematoxylin.
Statistics
Signiﬁcant differences in mRNA expression in endometrial biopsies was
determined by one-way ANOVA and Tukey’s post hoc analysis. These
data were logarithmically transformed prior to statistical analysis. Data
from reporter assays were statistically analysed using repeated measures
two-way ANOVA and Bonferroni’s post hoc analysis. Vehicle treatments
are not shown in ﬁgures as there was no statistical difference between
vehicle and control (without vehicle) samples in any of the experiments.
Fold changes quoted in the results section were calculated by comparison
to the untreated control for IL-1b and by comparison to DMSO (vehicle
control) for E2 and E2 þ IL-1b. Signiﬁcant differences in mRNA
expression in cell culture experiments were determined using repeated
measures two-way ANOVA and Bonferroni’s post hoc analysis.
Results
Expression of p65 and p105 mRNA in
endometrium is highest during the secretory
phase of the menstrual cycle
Quantitative RT–PCR analysis of well characterized endometrial biop-
sies showed that p65 mRNA expression is highest during the mid and
late secretory phases (Fig. 1A; P , 0.05). p105 mRNA expression
peaks during the late secretory phase of the menstrual cycle
(Fig. 1B; P , 0.05).
p65, p105/p50 and IkBa are widely expressed
in the human endometrium and are present
in both epithelial and stromal compartments
Immunoexpression of p65, p105/p50 and IkBa was detected in endo-
metrium at all stages of the menstrual cycle (Fig. 2: shows immunolo-
calization in a representative endometrial biopsy from the mid
.............................................................................................................................................................................................
Table I Details of endometrial biopsies
Cycle phase Number of samples E2 (pM), range median P4 (nM), range median
PROL 7 78.91–559.09, 311 0.97–5.91, 2.47
ES 5 289–599.12, 504.3 5.5–112.91, 80.5
MS 6 279–1949, 659.2 42.10–114.53, 78.6
LS 4 59.09–819, 172.1 1.06–11.29, 5.4
MENST 2 371, 223 7.54, 2.98
Cycle phase (as determined by the Noyes’ criteria) was consistent with circulating estradiol and progesterone concentrations at time of biopsy. PROL ¼ proliferative; ES, MS and LS ¼
early, mid and late secretory; MENST ¼ menstrual.
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localization at different menstrual cycle phases (data not shown).
Cytoplasmic staining was detected in both glandular and stromal com-
partments as well as in endothelial cells surrounding the blood vessels.
IL-1b and E2 interact to enhance
ERE-dependent reporter gene activity in
endometrial epithelial cells and this is ER
dependent
Initial studies conducted using endometrial adenocarcinoma Ishikawa
cells showed that treatment with E2 raised ERE activity 4-fold whereas
addition of IL-1b alone or in combination with E2 had no impact on
reporter gene activity (Supplementary data, Fig. S1; P , 0.01).
Incubation of TERT-EECs with 10
28 M E2 resulted in a 5-fold
increase in the ERE-dependent expression of luciferase (Fig. 3). In con-
trast with the Ishikawa cells, increased expression was also observed
when cells were treated with IL-1b alone and simultaneous exposure
to E2 and IL-1b increased ERE-luciferase reporter activity 15-fold
(Fig. 3; P , 0.01). Both basal ERE activity and the increased ERE
activity that occurred when TERT-EEC were treated with E2, IL-1b
or E2 þ IL-1b were abolished by the presence of the ER antagonist,
ICI 182720.
In complementary studies, NFkB response element activity was
increased when TERT-EEC were incubated with IL-1b alone. However,
incubationwithE2hadnoimpactonexpressionoftheluciferasereporter
and there was no evidence of an additive or synergistic effect when cells
were co-incubated with E2 and IL-1b (data not shown).
Activation of ERE-dependent reporter gene
activity by IL-1b is NFkB-dependent and the
interaction between NFkB and ER signalling
pathways may be mediated by either ERa or
ERb
In a similar experiment assessing ERE activation, the presence of a
dominant negative IkBa molecule reduced IL-1b-dependent increases
Figure 1 Differential mRNA expression of p65 and p105 in
endometrium from throughout the menstrual cycle.
P ¼ proliferative; ES ¼ early secretory; MS ¼ mid secretory; LS ¼ late
secretory. Same letters denote statistical signiﬁcance. (A) p65. p65 mRNA
expression is maximal during the mid and late secretory phase of the men-
strual cycle. ab: P , 0.05 (B) p105. p105 mRNA expression peaks in the late
secretory of the menstrual cycle. a: P , 0.05.
Figure 2 Immunolocalization of p65, p105/p50 and IkBa in endometrium from the mid secretory phase of the menstrual cycle.
There were no obvious changes in the pattern of localization in endometrial biopsies from across the menstrual cycle. The pattern of localization is demonstrated in a
representative endometrial biopsy from the mid secretory phase. (A) p65. (B) p50. (C)I kBa. Negative controls in insets. Scale bar ¼ 100 mm. ep ¼ epithelium;
s ¼ stroma; e ¼ endothelium.
NFkB and ER signalling in endometrium 513in ERE-luciferase gene expression when cells were incubated with
IL-1b alone or IL-1b plus E2 (Fig. 4A).
Treatment of TERT-EEC with the ERa selective agonist, PPT, or the
ERb selective agonist, DPN, increased ERE-luciferase reporter gene
expression 5-fold and 4-fold, respectively. When the cells were
treated with IL-1b in combination with PPT or DPN, ERE activity
was raised 13-fold and 12-fold, respectively (Fig. 4B; P , 0.001), and
these additive interactions were reduced by the presence of Ad-IkBa.
IL-1b and E2 act additively to enhance
expression of PGES and c-myc
Expression of PRAþB, c-myc, PGES and cyclin D1 in TERT-EEC was
examined after 2, 4 and 8 h of treatment. PRAþB mRNA expression
was signiﬁcantly increased by treatment with E2 at 4 and 8 h and
this was unaffected by treatment with IL-1b (Fig. 5A; P , 0.05).
c-myc mRNA expression was up-regulated 3.4-fold by treatment
with E2 alone at 8 h and this increase was enhanced in the presence
of IL-1b (6.7-fold increase, Fig. 5B; P , 0.05). Treatment with IL-1b
alone did not alter c-myc mRNA expression. Expression of PGES
mRNA in TERT-EEC was increased 2.7-fold and 4.8-fold by treatment
with E2 and IL-1b for 8 h, respectively. E2 and IL-1b acted together to
raise PGES mRNA expression by 9.5-fold (Fig. 5C; P , 0.001). Similar
effects of treatment were observed at 4 h. In contrast, cyclin D1
mRNA expression was increased 1.6-fold by treatment with E2 at
8 h and this response was not altered by the presence of IL-1b
(Fig. 5D; P , 0.01).
Discussion
To our knowledge, we report novel data detailing an additive inter-
action between the ER and NFkB signalling pathways in endometrial
epithelial cells derived from normal healthy endometrium
(Hombach-Klonisch et al., 2005). The increase in ERE activity could
be mediated by either ERa or ERb.
Previous studies have reported negative interactions between the
ER and NFkB pathways. Mutual repression of signalling between
NFkB and ER has been reported in various in-vitro systems (Harnish
et al., 2000; Feldman et al., 2007; Quaedackers et al., 2007). A
number of different mechanisms including direct interactions
between p65 and ER (Quaedackers et al., 2007), cofactor recruitment
(Harnish et al., 2000; Speir et al., 2000) and E2-mediated modulation
of IkBa levels (Sun et al., 1998) have been suggested to explain these
results. Direct interactions between ERa and p65 have been shown in
osteoblastic U2-OS cells (Quaedackers et al., 2007) although E2 pre-
vents degradation of IkBa by PMA treatment of HeLa cells (Sun et al.,
1998). The cofactors CBP and p300 are reported to mediate inter-
actions between NFkB and ER in human liver and coronary smooth
muscle cells, respectively (Harnish et al., 2000; Speir et al., 2000).
Mutual inhibition of NFkB and ER signalling has also been detailed in
an in-vivo mouse model of cardiovascular disease (Evans et al.,
2001). In a reproductive context, Feldman et al. (2007) have shown
Figure 4 The positive interaction between E2 and IL-1b in
TERT-EECs is NFkB dependent and can be mediated by ERa
and ERb.
Same lettersdenotestatisticalsigniﬁcance.(A)Cellsweretreated withE2,IL-1b
andE2 þ IL-1bintheabsenceandpresenceofaninhibitoroftheNFkBpathway
(Ad-IkBa; n ¼ 3). ac: P , 0.001; bde: P , 0.01. (B) Cells were treated with
PPT, DPN, IL-1b, PPT þ IL-1b and DPN þ IL-1b in the absence and presence
of Ad-IkBa (n ¼ 3). abeﬁj: P , 0.001; dh: P , 0.01; cg: P , 0.05.
Figure 3 E2 and IL-1b positively interact to enhance estrogen
response element (ERE) activity in an estrogen receptor (ER) depen-
dent manner in TERT-EECs.
Cells were treated with E2, IL-1b and E2 þ IL-1b in the absence and presence
of the ER antagonist, ICI 172820 (n ¼ 3). Same letters denote statistical signiﬁ-
cance. a: P , 0.001; bc: P , 0.01.
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after a 48 h treatment period and have suggested that there is also a
reciprocal inhibitory action of E2 on NFkB activity. In addition, it has
also been reported that NFkB activation reduces the response of both
Ishikawa and endometrial stromal cells to E2 (Guzeloglu-Kayisli et al.,
2008). In our current study, we did not ﬁnd any effect of IL-1b on ERE
activity in Ishikawa cells in the absence or presence of E2 at a 24 h
time point. These results are in contrast to the additive interaction
that occurs between the ER and NFkB pathways in TERT-EECs,
suggesting that the relationship between these two signalling pathways
is cell-type speciﬁc. This may be reﬂective of differences between cells
derived from the healthy endometrial epithelium and those derived
from adenocarcinomas or the stromal compartment and highlights
the importance of using untransformed cells to model normal endo-
metrial cell function.
Positive interactions between the ER and NFkB signalling pathways
have been described in some cell lines. For example, Frasor et al.
(2008) reported that E2 and TNFa or IL-1b act in synergy to
up-regulate PGES expression in the MCF-7 breast cancer cell line by
an ER- and NFkB-dependent mechanism, which involves increased
recruitment of both ERa and p65 to the ERE in the PGES promoter.
In the present study, we demonstrated that expression of PGES was
markedly up-regulated when TERT-EEC were incubated with E2 and
IL-1b, suggesting that p65 recruitment to the ERE may also occur in
our in-vitro model. Alternatively interactions between NFkB and ER
may be mediated via one of the mechanisms that have been documen-
ted to occur when there is a negative interaction between these sig-
nalling pathways (as detailed above). Further studies are necessary
to determine the molecular basis for the interaction between the
ER and NFkB pathways in TERT-EECs. The human prolactin promoter
contains a functional ERE and is synergistically activated by E2 and
TNFa in a reporter assay via an ER-dependent mechanism
(Adamson et al., 2008). Endogenous prolactin gene expression was
also increased synergistically by E2 and TNFa in that study.
However, a reporter assay using a consensus ERE-construct showed
that TNFa inhibited ERE activity in this case suggesting that the syner-
gistic interaction between TNFa and ER is speciﬁc to the prolactin
promoter (Adamson et al., 2008).
We found evidence of an additive interaction between E2 and IL-1b
regulated expression of PGES and c-myc, but the same treatment did
not have a similar impact on expression of PR or cyclin D1 in
TERT-EEC. We suggest that these differences are due to the presence
of different response elements in the promoter region of each gene. In
this context, previous studies have suggested that promoter elements
Figure 5 Regulation of endogenous gene expression by E2 and IL-1b in TERT-EECs.
Cells were treated with E2, IL-1b and E2 þ IL-1b (n ¼ 3). Same letters denote statistical signiﬁcance. (A)P R AþB. abcdehi: P , 0.05; fgj: P , 0.01 (B) c-myc. ade:
P , 0.001; c: P , 0.01; bf: P , 0.05. (C) PGES. af: P , 0.01; b: P , 0.05; cdeghij: P , 0.001;. (D) Cyclin D1. ab: P , 0.01.
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1990a, b; Guttridge et al., 1999; Takebayashi et al., 2003; Saitoh
et al., 2005; Condon et al., 2006; Ackerman et al., 2008) but that
their regulation by E2 is more complex. Notably ligand-activated
ERs can regulate gene expression directly via an ERE or indirectly by
interacting with other transcription factors including AP-1 and Sp1
(Gruber et al., 2004). ER-dependent regulation of PR is reported to
be mediated by both EREs and a Sp1 site (Chauchereau et al.,
1991; Petz et al., 2004). Although c-myc is considered to be an
E2-regulated early response gene, its promoter does not contain a
consensus ERE but its E2 responsiveness is reported to be mediated
via Sp1 binding (Dubik and Shiu, 1992). The PGES promoter is
reported to contain a functional ERE upstream of the transcription
start site (Frasor et al., 2008) although the responsiveness of cyclin
D1 to E2 is reported to involve AP-1, Sp1 and NFkB sites rather
than a consensus ERE (Castro-Rivera et al., 2001; Rubio et al., 2006).
A positive interaction between the ER- and NFkB-signalling path-
ways has also been reported to occur at kB sites. In the T47D
breast cancer cell line, E2 induces proliferation and cyclin D1
expression by an NFkB dependent mechanism, which is enhanced
in the presence of TNFa and involves the formation of a protein
complex containing ER, p65 and the coactivator RAC3 (Rubio et al.,
2006). In COS-1 cells, ERa and NFkB have also been found to have
a synergistic action at the 5-HT1A receptor promoter via NFkB
sites, although this study also showed that E2 represses the activity
of an NFkB response element in a synthetic construct, again suggesting
that the interaction between the pathways is promoter speciﬁc
(Wissink et al., 2001). In contrast, in our current study, we have not
found any evidence for a positive or negative effect of E2 on NFkB
reporter activity in TERT-EECs (data not shown).
During the putative implantation window, immunoexpression
studies have revealed that ERb is the predominant ER protein
present in the nuclei of glandular and surface epithelial cells in the func-
tional layer of the endometrium (Critchley et al., 2002; Bombail et al.,
2008). In the present study, we detected immunoexpression of the
NFkB proteins, p65 and p50, in the glandular epithelium in endome-
trium along with the inhibitor protein, IkBa. Our previous studies have
also demonstrated the presence of mRNA for the upstream kinases
MEKK1, NIK, IKKa and IKKb in endometrium with MEKK1 and
IKKa proteins localized to the glandular and, in some cases luminal,
epithelium (King et al., 2001). The expression of p65 and p50 has pre-
viously been reported to peak around the putative implantation
window (Laird et al., 2000; Page et al., 2002) on the basis of semi-
quantitative immunohistochemical studies. Our current quantitative
analysis of p65 and p105 mRNA expression in well characterized
endometrial biopsies is in agreement. It should be noted that these
quantitative PCR studies do not provide information regarding which
cellular compartment(s) are responsible for the increased expression
of p65 and p105 mRNA in the secretory phase. Leukocyte popu-
lations present in endometrium vary across the menstrual cycle
(Bulmer et al., 1991) and may contribute to the changes we have
documented. In any case, our current data, along with that previously
reported by others, suggest that the NFkB pathway may be involved in
the regulation of inﬂammatory events at implantation.
The IL-1 system is a key cytokine network that has an impact on
endometrial cell function at the time of implantation (Simon et al.,
1997; Fazleabas et al., 2004). Notably, IL-1 is produced by the
preimplantation embryo (Baranao et al., 1997) and the IL-1 receptor
type I is present in endometrial epithelium (Bigonnesse et al., 2001).
An IL-1 receptor antagonist has been shown to prevent implantation
in mice (Simon et al., 1994) although a further study did not report a
similar effect (Abbondanzo et al., 1996). Our data suggest that IL-1
may augment the actions of E2 on the endometrial epithelium in
vivo. This could be a mechanism to allow the developing blastocyst
to modulate the function of the endometrial epithelium enhancing
the likelihood of successful implantation (Fig. 6). For example, both
cyclo-oxygenase and PGES enzymes are present in the human endo-
metrial epithelium during the implantation window (Jones et al.,
1997; Marions and Danielsson, 1999; Milne et al., 2001). Prostaglan-
dins increase vascular permeability, modulate decidualization and regu-
late the immune response at implantation (Tranguch et al., 2005;
Kennedy et al., 2007). Our data suggest that E2 and IL-1b may act
additively to increase the production of PGE2 by up-regulating PGES
expression in the endometrial epithelium. We recognize that pro-
gesterone may also impact the ER and NFkB signalling pathways at
implantation. However, the endometrial epithelium does not
express the PR during the implantation window, so progesterone
actions would be mediated via the stromal compartment (Wang
et al., 1998). Although the TERT-EECs do express the PR, examination
of progesterone effects in our in-vitro epithelial cell model would not
be representative of the environment in vivo.
In summary, we have identiﬁed a novel positive interaction between
the ER- and NFkB-dependent signalling pathways in an endometrial
epithelial cell line derived from healthy endometrium. NFkB activation
modulates ERE activity by an ER and NFkB dependent mechanism and
can enhance ER-mediated endogenous gene expression in an in-vitro
human endometrial epithelial cell model. The positive interaction
Figure 6 Summary of the potential interactions between the ER
and NFkB signalling pathways in endometrial epithelial cells.
E2 and IL-1b positively interact to enhance ERE activity in the endometrial epi-
thelium and to up-regulate expression of a subset of genes, including PGES.
This mechanism may allow the developing blastocyst, which produces IL-1,
to modulate gene expression in the endometrial epithelium, enhancing the like-
lihood of successful implantation.
516 King et al.between NFkB and ER may be involved in the regulation of epithelial
cell function at implantation and aberrant interactions between these
signalling pathways may be involved in pathologies such as early preg-
nancy failure and infertility.
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